July 17th, 2024 | 06:30 CEST
BioNTech, Cardiol Therapeutics, Bayer - Prepared for the next wave
The assassination attempt on former and possibly future US President Donald Trump was clearly the dominant topic at the weekend, causing both gold and the largest cryptocurrencies to surge at the start of the week. Still largely unnoticed, however, the COVID-19 figures are rising again, especially in the United States, which could halt the downward spiral for vaccine manufacturers such as BioNTech/Pfizer and Moderna.
time to read: 4 minutes
|
Author:
Stefan Feulner
ISIN:
BIONTECH SE SPON. ADRS 1 | US09075V1026 , CARDIOL THERAPEUTICS | CA14161Y2006 , BAYER AG NA O.N. | DE000BAY0017
Table of contents:
"[...] Defence will continue to develop its Antibody Drug Conjugates "ADC" and its radiopharmaceuticals programs, which are currently two of the hottest products in demand in the pharma industries where significant consolidations and take-overs occurred. [...]" Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.
Author
Stefan Feulner
The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.
Tag cloud
Shares cloud
BioNTech - New wave on the way?
Since the pandemic subsided, the shares of the Mainz-based biotech company have also been on a steep downward trend. Since peaking at USD 464.00 in August 2021, the share price has lost around 82% of its value and, at USD 84.95, is only marginally above its low for the year of USD 80.09. There is currently no all-clear that the vaccine manufacturer will not see even lower prices. Should BioNTech shares slip below the lower limit of the wedge formation that has formed since February 2023, currently at USD 79.65, further stop-loss levels will likely fall. The next significant resistance level is USD 64.45. On the upside, this formation would be resolved if the USD 101.29 mark were to be overcome on a sustained basis. The EMA 50 also runs in this area.
There is currently light on the horizon from the US Center for Disease Control and Prevention (CDC). It sees increasing infection figures in 44 US states. According to the latest hospital reports published at the end of June, hospital admissions associated with COVID-19 rose by 23.3% week-on-week. The number of deaths due to the virus also rose by 14.3%.
The new virus variants KP.2 and KP.3, which are now responsible for over half of all new infections, require particular attention. These variants show increased transmissibility compared to earlier strains. This has led to a reassessment of the situation by the US CDC. While the initial focus was on vaccines against the JN.1 virus strain, attention is now turning to combating the more aggressive KP.2 variant. Pharmaceutical companies such as Moderna, Novavax, and Pfizer/BioNTech have already pledged to follow the CDC's recommendations and adapt their developments accordingly.
CARDIOL THERAPEUTICS - DISCREPANCY IN VALUATION AMIDST BREAKTHROUGH CLINICAL ACHEIVEMENTS
When analyzing the prevailing circumstances of the clinical-stage life sciences company Cardiol Therapeutics, it is challenging to understand the significant gap in market valuation despite positive clinical data. The company is dedicated to the research and clinical development of anti-inflammatory and anti-fibrotic therapeutics for the treatment of heart disease with the promising drug candidate CardiolRx™.
Following the announcement of promising 8-week topline data from their open-label Phase II MAvERIC-Pilot study, which investigated the efficacy and safety of CardiolRx™ in recurrent pericarditis, Cardiol’s share price has fallen by roughly 32% from its interim high of CAD 4.26 on June 12, 2024, to its current level of CAD 2.90. This market reaction is perplexing given that the reported clinical data in the 27 patients showed a substantial reduction in patient-reported pericarditis pain and a normalization of C-reactive protein (CRP), an inflammatory marker, in 80% of those treated. CardiolRx™ notably achieved marked reductions in pericarditis pain and inflammation, displaying a magnitude of effect comparable to the commonly used third-line immunosuppressive biologic therapies for recurrent pericarditis.
Capitalizing on the dip in share price, President and CEO David Elsley increased his share position by acquiring an additional 50,000 shares at a price of CAD 2.77, thereby expanding his holding to 1,204,500 shares. Analyst firms covering Cardiol Therapeutics have identified the current valuation to be grossly undervalued. Analyst Edward Nash of Canaccord Genuity has responded to the recent results with an issued price target of CAD 10.92. Analyst Douglas Loe of Leede Jones Gable revised their price target from CAD 4.50 to CAD 11.00. Furthermore, ROTH analyst Jason Wittes initiated coverage on the company with a buy rating and USD 10.00 price target.
The discrepancy between the Company, capitalized at CAD 200.08 million, and its peer group is dramatic. Recently, competitor Cardior Pharmaceuticals was acquired by Novo Nordisk for around USD 1 billion.
Bayer - Tense situation
Bayer shares have been working on bottoming out for months, but there is still no sign of the trend reversal that many investors are hoping for. The chart has formed a falling triangle, suggesting another test of the yearly lows at EUR 24.96 and a further sell-off. The share is also facing headwinds from the relative strength index RSI, which is turning down again and could generate a further sell signal.
In recent days, the US Food and Drug Administration (FDA) has offered a glimmer of hope, having granted "fast-track status" to a gene therapy for Parkinson's patients developed by Bayer subsidiary Asklepios BioPharmaceutical.
The AB-1005 gene therapy, the development of which Bayer began in 2020 with the acquisition of Asklepios BioPharmaceutical, could reach the market more quickly thanks to its fast-track status. However, it should be noted that the status initially only relates to the Phase I trial, which evaluates the therapy's safety. Whether the subsequent, much more costly and extensive Phase II and Phase III trials in humans will also be successful is likely to take years.
BioNTech's share price is approaching its low for the year, but the news of the increase in COVID-19 figures could provide some relief. Bayer is also still struggling from a technical perspective. Analysts see multiplication potential after successful trial data for Cardiol Therapeutics.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.